Harel Insurance Investments & Financial Services’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Harel Insurance Investments & Financial Services’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-6	Closed	–	–	556
2019 Q4	$0	Buy	+6	New	+$5	﹤0.01%	585
2018 Q4	–	Sell	-39,000	Closed	-$180K	–	552
2018 Q3	$180K	Hold	39,000	–	–	0.01%	212
2018 Q2	$179K	Hold	39,000	–	–	0.01%	194
2018 Q1	$281K	Hold	39,000	–	–	0.02%	180
2017 Q4	$328K	Hold	39,000	–	–	0.02%	169
2017 Q3	$328K	Hold	39,000	–	–	0.03%	134
2017 Q2	$398K	Hold	39,000	–	–	0.03%	122
2017 Q1	$460K	Sell	39,000 -17,000	-30%	-$193K	0.04%	93
2016 Q4	$717K	Buy	56,000 +5,000	+10%	+$79.3K	0.1%	62
2016 Q3	$510K	Buy	51,000 +15,000	+42%	+$190K	0.07%	77
2016 Q2	$396K	Buy	+36,000	New	+$707K	0.05%	102

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Harel Insurance Investments & Financial Services's NAVB Position: Q1 2020 in Review

Harel Insurance Investments & Financial Services sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2020, closing a stake of 6 shares.

Harel Insurance Investments & Financial Services first reported a position in NAVB in Q2 2016 and held it in 11 quarters. The position peaked at $717K in Q4 2016. 29 funds tracked by Wall St. Rank hold NAVB as of Q1 2020.

Harel Insurance Investments & Financial Services reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2020 after selling out during the quarter.
Harel Insurance Investments & Financial Services sold 6 Navidea Biopharmaceuticals Inc. shares in Q1 2020.
Harel Insurance Investments & Financial Services first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2016 and held it in 11 quarters.
Harel Insurance Investments & Financial Services's Navidea Biopharmaceuticals Inc. position peaked at $717K in Q4 2016.
29 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2020.

Based on Harel Insurance Investments & Financial Services's 13F filing for Q1 2020, filed 28 Apr 2020.